Abstract
This cost-of-illness analysis based on information from 1.549 patients in The Netherlands is part of a Europe-wide study on the costs of multiple sclerosis (MS). The objective was to analyze the costs and quality of life (QOL) related to the level of disease severity and progression. Patients from three specialized MS centres participated in the survey by answering a mail questionnaire (response rate, 52%). In addition to details on the disease (type of disease, relapses, level of functional disability), the questionnaire asked for information on all resource consumption, medical, non-medical, work absence, early retirement and informal care as well as QOL (expressed as utility). The mean age of the cohort was 47 years, and 7.6% of patients were 65 years of age or more. Forty-eight percent of patients had mild disease [Expanded Disability Status Scale (EDSS) score of 0–3], 40% moderate disease (EDSS score of 4–6.5) and 11% severe disease (EDSS score of 7 and above). The mean EDSS score in the sample was 3.9 (median 4.0), with a utility of 0.61. Costs and utility are highly correlated with disease severity. Workforce participation decreases from around 75 to 80% in early disease to less than 5% in the very late stages. Hospitalization is very infrequent in early disease, representing less than € 500 per year for patients at EDSS scores below 6, but increases steeply for patients at an EDSS score of 7 and above. Ambulatory care increases fivefold between early and late disease, while services rise from basically no cost to almost € 8.000 per year at an EDSS score of 7 and € 19.000 per year at EDSS scores of 8–9. Productivity losses are multiplied by 10 in late disease, while informal care increases from € 300 per year at EDSS scores of 0–1 to nearly € 15.000 per year at EDSS scores of 8–9. Hence, total mean costs per patient are driven essentially by the distribution of the severity levels in the sample, increasing from € 9.300 per year at EDSS scores of 0–1 to € 50.000 per year at an EDSS score of 7 and € 78.000 per year at EDSS scores of 8–9. The same is true for utility, which decreases from 0.85 to 0.05 as the disease becomes severe. However, the utility loss compared to the age- and gender-matched general population is high at all levels of the disease (0.25 at an EDSS score of 2 to 0.4 at EDSS scores of 5–6), leading to an estimated annual loss of 0.24 quality-adjusted life-years (QALYs) per patient. Relapses for patients with an EDSS score below 5 are associated with a cost of around € 2.800 and a utility loss of 0.15 during the quarter in which they occur.
Similar content being viewed by others
References
Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B (2006) Costs and quality of life of multiple sclerosis in Europe. J Neurol ( In press)
Koopmanschap M, Rutten F, Vanineveld B, Vanroijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Econ 14: 171–189
Dean G (1994) How many people in the world have multiple sclerosis? Neuroepidemiology 13: 107
Minderhoud J, Zwanniken C (1994) Increasing prevalence and incidence of multiple sclerosis: an epidemiological study in the province of Groningen, The Netherlands. In: Lauer W (ed) Multiple sclerosis: an epidemiological update. Leuchtturm, Darmstadt, pp 113–121
Pugliatti M, Rosati G, Carton H et al. (2006) The prevalence and incidence of multiple sclerosis in Europe. Eur J Neurol 13: 1–23
Kurtzke J (1983) Rating neurological impairment in multiple sclerosis and expanded disability status scale (EDSS). Neurology 33: 1444–1452
Prange A, Lauer K, Poser S et al. (1986) Epidemiological aspects of multiple sclerosis: a comparative study of four centers in Europe. Neuroepidemiology 5: 71–79
The EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16: 199–208
Dolan P, Gudex C, Kind P, Williams A (1995) A social tariff for EuroQol. results from a UK general population survey. Research Report 138 (York, Centre for Health Economics, University of York)
Hakkaart-Vanroyen L, Hoeijenbos M, Regeer E, Al E (2004) The societal costs and quality of life of patients suffering from bipolar disorder in The Netherlands. Acta Psychiatr Scand 110: 383–392
Ostenbrink J, Bouwmans C, Koopmansschap M (2004) Handleiding voor Kostenonderzoek. iMTA Erasmus University Medical Center, Rotterdam, in opdracht van College voor Zorgvoorzieningen
Henriksson F, Fredrikson S, Jönsson B (2000) Costs, quality of life and disease severity in multiple sclerosis – a cross-sectional study in Sweden. SSE/EFI Working Paper Series in Economics and Finance No. 361. Stockholm School of Economics; Stockholm, Sweden
Kobelt G, Lindgren P, Smala A, Jönsson B, Group Gms (2001) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. Eur J Health Econ 2: 60–68
Kobelt G, Lindgren P, Parkin D, Jönsson B (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. SSE/EFI Working Paper Series in Economics and Finance No. 398. Stockholm School of Economics; Stockholm, Sweden
Eichler H, Kong S, Gerth W et al. (2004) Use of cost-effectiveness analysis in health care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7: 518–528
Koopmanschap M, Vanineveld B (1992) Towards a new approach for estimating indirect cost of disease. Soc Sci Med 34: 1005–1010
Johannesson M, Karlsson G (1997) The friction cost method: a comment. J Health Econ 16: 249–255
Liljas B (1998) How to calculate indirect costs in economic evaluations. Pharmacoeconomics 13: 1–7
Pauly M, Nicholson S, Xu J et al (2002) A general model of the impact of absenteeism on employers and employees. Health Econ 11: 221–231
Nicholson S, Pauly M, Polsky D et al. (2006) Measuring the effects of work loss on productivity with team production. Health Econ 15: 111–123
Contributions:
Bert Anten (Maaslandziekenhuis, Sittard); Mattias Ekman (Stockholm Health Economics, Sweden); Peter JH Jongen (MS Centre, Nijmegen); Chris Polman (Free University Medical Centre, Amsterdam); Bernard Uitdehaag (Free University Medical Centre, Amsterdam)
Acknowledgements
Leona Hakkaart-VanRoijen (iMTA, Erasmus University, Rotterdam); Ulrika Lilja (Stockholm Health Economics, Sweden)
Conflict of interest
No information supplied.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s10198-007-0072-3.
Rights and permissions
About this article
Cite this article
Kobelt, G., Berg, J. & Lindgren , P. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ 7 (Suppl 2), 55–64 (2006). https://doi.org/10.1007/s10198-006-0378-6
Issue Date:
DOI: https://doi.org/10.1007/s10198-006-0378-6